Ingrid Glimelius

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Jag är överläkare i Onkologi och arbetar med patienter som har drabbats av
lymfom eller testikelcancer. Jag arbetar som läkare på onkologkliniken,
Akademiska Sjukhuset Uppsala.
Utöver detta bedriver jag forskningsstudier med syfte att förbättra för
de som drabbats av dessa cancersjukdomar.
Sedan 2002 har jag varit involverad i lymfomforskning och sedan 2011 har jag
samarbetat med Karin Ekström Smedby (https://ki.se/people/kariek [1]) och
varit anknuten till cancerepidemiologigruppen vid Enheten för Klinisk
Epidemiologi, Karolinska Institutet. Utöver mitt kliniska arbete är jag
ansvarig för kliniska fas I-III studier, epidemiologiska studier och
handleder doktorander. Jag har ett stort intresse för undervisning och
undervisar både läkarstudenter och blivande specialistläkare
Leg Läkare, Uppsala Universitet 2001
PHD, Uppsala Universitet 2009, Avhandling: /Hodgkin lymphoma – an
interplay between tumour cell and microenvironment./
Specialist Internmedicin 2011
Specialist Onkologi 2013
Docent i Onkologi 2016
Good Clinical Practice, Investigator Site Personnel ICH-GCP
Överläkare Onkologi 2019
Lektor Uppsala Universitet 2021-
[1] https://ki.se/people/kariek

Forskningsbeskrivning

En beskrivning av min forskning finns på den engelskspråkiga sidan
https://ki.se/en/people/inggli [1].
[1] https://ki.se/en/people/inggli

Undervisning

Jag undervisar på läkarutbildningen och handleder regelbundet
läkarstudenter samt blivande specialistläkare framförallt om orsak,
diagnostik, behandling och omhändertagande av patienter med olika lymfatiska
maligniteter.
Kursanvarig läkarutbildningen i Onkologi Uppsala Universitet 2012
Högskolepedagogisk Grundkurs 2014
Good Clinical Practice, Investigator Site Personnel ICH-GCP
Examinator projektarbeten läkarutbildningen Uppsala Universitet, sedan 2017-
Bred undervisningserfarenhet på både grund och specialiserad nivå
Styrgruppen för Nationella Forskar Skolan i Onkologi, NATION 2019-
Immunterapi och tumörens mikromiljö, kursansvarig 2019-

Artiklar

Journal article: BRITISH JOURNAL OF CANCER. 2025;133(5):655-664
Association of change in physical activity with use of outpatient specialist care and hospitalisations among breast cancer survivors with type 2 diabetes in Sweden
Allen G; Heiland EG; Teleka S; Glimelius I; Michaelsson K; Byberg L; Brooke HL
Article: JOURNAL OF CANCER SURVIVORSHIP. 2025;19(4):1244-1254
Long-term prescribed drug use in stage I-III rectal cancer patients in Sweden, with a focus on bowel-regulating drugs after surgical and oncological treatment
Boman SE; Fuentes S; Nordenvall C; Martling A; Chen L; Glimelius I; Neovius M; Smedby KE; Eloranta S
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2025;117(6):1134-1141
Mortality after cancer diagnosis among children with congenital heart disease in Denmark and Sweden
Kampitsi C-E; Kenborg L; Mogensen H; Broberg O; Glimelius I; Erdmann F; Winther JF; Feychting M; Tettamanti G
Article: HEMASPHERE. 2025;9(3):e70101
Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial
Forsgren E; Jorgensen RRK; Bentzen H; Riise J; Haaber J; Pasanen A; Kuitunen H; Wader KF; El-Galaly TC; Hutchings M; Glimelius I; Jerkeman M
Journal article: LANCET ONCOLOGY. 2025;26(2):150-152
Mantle cell lymphoma: is it time for risk-adapted treatment?
Glimelius I
Journal article: HEMASPHERE. 2025;9(1):e70080
Limited stage mantle cell lymphoma: A real-world study of primary treatment and prognosis in Sweden 2006-2018
Albertsson-Lindblad A; Ekberg S; Glimelius I; Ellin F; Sonnevi K; Lewerin C; Brandefors L; Smedby KE; Jerkeman M
Journal article: BLOOD CANCER JOURNAL. 2024;14(1):222
Clinical characteristics and outcomes of 476 mantle cell lymphoma patients aged 80 years and older
Pahnke S; Abalo KD; Ekberg S; Albertsson-Lindblad A; Smedby KE; Jerkeman M; Glimelius I
Article: EJHAEM. 2024;5(6):1190-1200
Congestive heart failure after anthracycline-containing treatment for Hodgkin lymphoma: A Swedish matched cohort study
Baech J; El-Galaly TC; Entrop JP; Glimelius I; Molin D; Godtfredsen SJ; Crowther MJ; Smedby KE; Eloranta S; Dietrich CE
Journal article: BLOOD. 2024;144:235
Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich
Lewis DJ; Jerkeman M; Sorrell L; Wright D; Glimelius I; Pasanen A; Christensen JH; Wader KF; Davies AJ; Morley N; Mcnamara C; Poulsen CB; Riise J; Sonnevi K; Lagerloef I; Burton C; Dalal S; Rawstron A; Tute RMD; Allgar V; Aroori S; Warner M; Wainman B; Scully C; Sanders J; Niemann CU; Toldbod H; Crosbie N; Bishton MJ; Eyre TA; Rule S
Journal article: BLOOD. 2024;144:4370
Plasma Proteomics Differentiates between Patients with B-Cell Lymphomas
Babacic H; Chowdhury NM; Berglund M; Hashemi J; Collin J; Pettersson E; Ly A-M; Nikkarinen A; Enblad G; Molin D; Glimelius I; Pernemalm M; Hellstroem M
Journal article: BLOOD. 2024;144:1623
Plasma Proteomic Profiling Identifies Prognostic Biomarkers in Mantle Cell Lymphoma
Selvin T; Nylund P; Ly A-M; Nikkarinen A; Berglund M; Abalo KD; Molin D; Enblad G; Hollander P; Hellstroem M; Glimelius I
Journal article: BLOOD. 2024;144:2995
Rule-Based Machine Learning Analysis of the Blood Proteome Identifies MCL Patients with High Risk of Early Disease Progression
Nylund P; Abalo KD; Zubair S; Voutsinou E; Selvin T; Ly A-M; Nikkarinen A; Berglund M; Molin D; Enblad G; Hollander P; Hellstrom M; Glimelius I
Journal article: BLOOD. 2024;144:1638
Survival in Mantle Cell Lymphoma Patients with a Second Primary Malignancy
Abalo KD; Trap T; Baech J; Ekberg S; Pahnke S; Albertsson-Lindblad A; Smedby KE; Jerkeman M; Brown P; Larsen TS; Gronbaek K; El-Galaly TC; Glimelius I
Journal article: BLOOD. 2024;144:3025
Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study
Paszkiewicz-Kozik E; Moreira C; Turgut M; Garrido M; Glimelius I; Lee ST; Sawalha Y; Ren Y; Ryland K; Ogbu UC; Villa D
Journal article: BLOOD. 2024;144:4405
Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study
Glimelius I; Kim WS; Paszkiewicz-Kozik E; Ernst D; Merryman RW; Moreira C; Tu S; Ren Y; Ryland K; Ogbu UC; Zinzani PL
Journal article: BLOOD. 2024;144:3014
Timing of Disease Progression and Impact on Survival in Mantle Cell Lymphoma: A Novel Illness-Death Model Study from the Swedish Mclcomplete Project
Ekberg S; Glimelius I; Albertsson-Lindblad A; Smedby KE; Jerkeman M; Dietrich CE
Journal article: BLOOD. 2024;144:1857
Incidence of Infections and Survival Outcomes in Patients with Multiple Myeloma and Chronic Lymphocytic Leukemia in Sweden: A Nationwide Population-Based Study of More Than 15,000 Patients
Glimelius I; Taetting L; Freilich J; Stelmaszuk MN; Yang Q; Deleskog A; Kristinsson SY
Journal article: BLOOD. 2024;144:747
Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial
Jerkeman M; Wader KF; Glimelius I; Pasanen A; Kim WS; Hansen LK; Riise J; Hutchings M; Elhussein HH; Niemann CU; Jorgensen RRK; El-Galaly TC; Ehinger M; Beiske K; Amini R-M; Moller MB; Karjalainen-Lindsberg M-L; Christensen JH
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2024;205(5):1794-1803
Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers
Forsgren E; Ekberg S; Smedby KE; Nylund P; Sjoblom T; Flogegard M; Sjostrom S; Hultdin M; Hallen K; Hellstrom M; Molin D; Enblad G; Glimelius I
Article: EJHAEM. 2024;5(5):998-1004
Medical history and lifestyle factors have limited impact on time-to-first-treatment in patients with chronic lymphocytic leukemia
Glimelius I; Kleinstern G; Robinson DP; Mansouri L; Rostgaard K; Hjalgrim H; Niemann CU; Mattsson M; Rabe KG; Hampel PJ; Parikh SA; Rosenquist R; Cerhan JR; Slager SL; Smedby KE
Article: BLOOD. 2024;144(9):1001-1009
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study
Malinverni C; Bernardelli A; Glimelius I; Mirandola M; Smedby KE; Tisi MC; Gine E; Albertsson-Lindblad A; Marin-Niebla A; Di Rocco A; Moita F; Sciarra R; Basic-Kinda S; Hess G; Ohler A; Eskelund CW; Re A; Ferrarini I; Kolstad A; Raty R; Quaglia FM; Eyre TA; Scapinello G; Stefani PM; Morello L; Nassi L; Hohaus S; Ragaini S; Zilioli VR; Bruna R; Cocito F; Arcari A; Jerkeman M; Visco C
Article: BLOOD ADVANCES. 2024;8(16):4370-4385
CD163*macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression
Rodrigues JDM; Lokhande L; Olsson LM; Hassan M; Johansson A; Janska A; Kumar D; Schmidt L; Nikkarinen A; Hollander P; Glimelius I; Porwit A; Gerdtsson AS; Jerkeman M; Ek S
Article: EJHAEM. 2024;5(4):820-824
Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma - A case report
Nikkarinen A; Glimelius I
Article: CANCER CAUSES & CONTROL. 2024;35(8):1101-1109
Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer
Skoeld C; Corvigno S; Dahlstrand H; Enblad G; Mezheyeuski A; Sundstroem-Poromaa I; Stalberg K; Tolf A; Glimelius I; Koliadi A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2024;205(2):542-551
Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study
Vandtved JH; Ovlisen AK; Baech J; Weinrich UM; Severinsen MT; Maksten EF; Jakobsen LH; Glimelius I; Kamper P; Hutchings M; Specht L; Dahl-Sorensen R; Christensen JH; El-Galaly TC
Article: ACTA ONCOLOGICA. 2024;63:563-572
The National Swedish Lymphoma Register - a systematic validation of data quality
Smedby KE; Eloranta S; Wasterlid T; Falini V; Jerlstrom U; Ellin F; Papworth K; Westerberg J; Lewerin C; Andersson P-O; Kristjansdottir HL; Brandefors L; Morth C-L; Hallen K; Kuric N; Abu Sabaa A; Wahlin BE; Molin D; Enblad G; Horsted A-S; Jerkeman M; Glimelius I
Article: HEMASPHERE. 2024;8(7):e121
Infections in patients with mantle cell lymphoma
Abalo KD; Ekberg S; Andersson TML; Pahnke S; Albertsson-Lindblad A; Smedby KE; Jerkeman M; Glimelius I
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2024;65:13-19
Primary Retroperitoneal Lymph Node Dissection as Treatment for Low-volume Metastatic Seminoma in a Population-based Cohort: The Swedish Norwegian Testicular Cancer Group Experience
Thor A; Negaard HFS; Bergdahl AG; Almas B; Larsen SM; Lundgren P-O; Gerdtsson A; Halvorsen D; Johannsdottir B; Jansson AK; Hellstrom M; Wahlqvist R; Langberg CW; Hedlund A; Akre O; Glimelius I; Stahl O; Haugnes HS; Cohn-Cedermark G; Kjellman A; Tandstad T
Article: BJU INTERNATIONAL. 2024;133(6):717-724
Initial surveillance in men with marker negative clinical stage IIA non-seminomatous germ cell tumours
Gerdtsson A; Negaard HFS; Almas B; Bergdahl AG; Cohn-Cedermark G; Glimelius I; Halvorsen D; Haugnes HS; Hedlund A; Hellstrom M; Holmberg G; Karlsdottir A; Kjellman A; Larsen SM; Thor A; Wahlqvist R; Stahl O; Tandstad T
Article: CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY. 2024;46:100785
Stable use of radiotherapy in lymphoma patients over time - A comprehensive national overview of radiotherapy use in Sweden with focus on older patients
Glimelius I; Ekberg S; Smedby KE; Wasterlid T
Article: CANCER CAUSES & CONTROL. 2024;35(5):741-747
Associations between pregnancy-related factors and birth characteristics with risk of rare uterine cancer subtypes: a Nordic population-based case-control study
Abril J; Trabert B; Troisi R; Grotmol T; Ekbom A; Engeland A; Gissler M; Glimelius I; Madanat-Harjuoja L; Ording AG; Sorensen HT; Tretli S; Bjorge T
Article: HAEMATOLOGICA. 2024;109(4):1171-1183
MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53-a Nordic Lymphoma Group study
Rodrigues JM; Hollander P; Schmidt L; Gkika E; Razmara M; Kumar D; Geisler C; Gronbaek K; Eskelund CW; Raty R; Kolstad A; Sundstrom C; Glimelius I; Porwit A; Jerkeman M; Ek S
Article: JCO CLINICAL CANCER INFORMATICS. 2024;8:e2300255
Machine Learning-Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma
Jorgensen RRK; Bergstroem F; Eloranta S; Severinsen MT; Smeland KB; Fossa A; Christensen JH; Hutchings M; Bo Dahl-Sorensen R; Kamper P; Glimelius I; Smedby K; Parsons S; Rodday AM; Maurer M; Evens A; El-Galaly T; Jakobsen LH
Journal article: ANNALS OF ONCOLOGY. 2024;35(3):245-247
Hit hard and remove treatment- this treatment strategy in Hodgkin Lymphoma promises less fatigue and less sick-leave
Glimelius I
Article: BLOOD ADVANCES. 2024;8(2):407-415
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial
Jerkeman M; Kolstad A; Hutchings M; Pasanen A; Meriranta L; Niemann CU; Jorgensen RRK; El-Galaly TC; Riise J; Leppa S; Christensen JH; Sonnevi K; Pedersen LB; Wader KF; Glimelius I
Article: INTERNATIONAL JOURNAL OF EPIDEMIOLOGY. 2023;52(6):1826-1835
Cancer risk in the siblings of individuals with major birth defects: a large Nordic population-based case-control study
Daltveit DS; Klungsoyr K; Engeland A; Ekbom A; Gissler M; Glimelius I; Grotmol T; Madanat-Harjuoja L; Ording AG; Sorensen HT; Troisi R; Bjorge T
Article: ACTA ONCOLOGICA. 2023;62(12):1707-1715
Strict self-isolation did not protect Swedish cancer patients on active treatment from the risk of becoming seropositive for SARS-CoV-2
Ginman B; Pahnke S; Freyhult E; Hoffman T; Kolstad L; Ronnberg B; Lundkvist A; Levedahl KH; Enblad G; Glimelius I
Article: EUROPEAN JOURNAL OF CANCER. 2023;195:113403
Secondary malignancies among mantle cell lymphoma patients
Abalo KD; Smedby KE; Ekberg S; Eloranta S; Pahnke S; Albertsson-Lindblad A; Jerkeman M; Glimelius I
Journal article: BLOOD. 2023;142:1656
An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma
Wang Y; Larson MC; Farooq U; Ekberg S; Smedby KE; Simonsen MR; Niemann CU; Zhao EJ; Gerrie AS; Switchenko JM; Bond DA; Bachanova V; Barta SK; Hill BT; Martin P; Danilov A; Grover NS; Karmali R; Ghosh N; Fenske TS; Kahl BS; Albertsson-Lindblad A; Glimelius IC; Al-Mashhadi AL; Larsen TS; Maddocks KJ; Link BK; Paludo J; Nowakowski GS; Habermann TM; Maurer MJ; Villa D; Cohen JB; El-Galaly TCC; Jerkeman M; Cerhan JR
Journal article: BLOOD. 2023;142:1729
Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1
Vose JM; Feldman T; Chamuleau MED; Kim WS; Lugtenburg P; Kim TM; Costa PA; Cheah CY; Glimelius IC; Hess B; Jurczak W; Musuraca G; Olszewski AJ; Dinh M; Kilavuz N; Wielgos-Bonvallet M; Li T; Li Z; Eskelund C; Farooq U
Article: BLOOD ADVANCES. 2023;7(18):5304-5313
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma
Nikkarinen A; Lokhande L; Amini R-M; Jerkeman M; Porwit A; Molin D; Enblad G; Kolstad A; Raety R; Hutchings M; Weibull CE; Hollander P; Ek S; Glimelius I
Article: BJU INTERNATIONAL. 2023;132(3):329-336
Validation of a prediction model for post-chemotherapy fibrosis in nonseminoma patients
Gerdtsson A; Torisson G; Thor A; Bergdahl AG; Almas B; Hakansson U; Tornblom M; Negaard HFS; Glimelius I; Halvorsen D; Karlsdottir A; Haugnes HS; Larsen SM; Holmberg G; Wahlqvist R; Tandstad T; Cohn-Cedermark G; Stahl O; Kjellman A
Article: INTERNATIONAL JOURNAL OF CANCER. 2023;153(4):723-731
Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study
Entrop JP; Weibull CE; Smedby KE; Jakobsen LH; Ovlisen AK; Molin D; Glimelius I; Marklund A; Holte H; Fossa A; Smeland KB; El-Galaly TC; Eloranta S
Article: HEMASPHERE. 2023;7(8):e928
Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma: The Swedish MCLcomplete Project
Jerkeman M; Ekberg S; Glimelius I; Albertsson-Lindblad A; Entrop JP; Ellin F; Sonnevi K; Lewerin C; Brandefors L; Smedby KE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2023;202(4):785-795
Reproduction patterns among non-Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population-based matched cohort study
Entrop JP; Weibull CE; Smedby KE; Jakobsen LH; Ovlisen AK; Glimelius I; Marklund A; Larsen TS; Holte H; Fossa A; Smeland KB; El-Galaly TC; Eloranta S
Article: BRITISH JOURNAL OF CANCER. 2023;128(12):2261-2269
Risk and mortality of testicular cancer in patients with neurodevelopmental or other psychiatric disorders
Jansson AK; Soderling J; Reutfors J; Thor A; Skold C; Cohn-Cedermark G; Stahl O; Smedby KEE; Pettersson A; Glimelius I
Journal article: INTERNATIONAL JOURNAL OF EPIDEMIOLOGY. 2023;52(3):966
Sex differences in childhood cancer risk among children with major birth defects: a Nordic population-based nested case-control study (vol 52, pg 450, 2023)
Daltveit DS; Klungsoyr K; Engeland A; Ekbom A; Gissler M; Glimelius I; Grotmol T; Madanat-Harjuoja L; Ording AG; Sorensen HT; Troisi R; Bjorge T
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(16_SUPPL):5008
Primary retroperitoneal lymph node dissection (RPLND) in seminoma stage IIA-IIC ≤3cm: Combined results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne.
Tandstad T; Kjellman A; Almas B; Grenabo Bergdahl A; Cohn-Cedermark GE; Gerdtsson A; Glimelius I; Halvorsen DL; Haugnes HSS; Hedlund A; Karlsdottir A; Larsen SM; Negaard HFS; Pfister D; Stahl O; Thor A; Wahlquist R; Heidenreich A; Paffenholz P; Seelemeyer F
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41 Suppl 2:474-475
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
Visco C; Malinverni C; Florea E; Glimelius I; Mirandola M; Ekström-Smedby K; Tisi MC; Giné E; Albertsson-Lindblad A; Niebla AM; Di Rocco A; Moita F; Sciarra R; Bašić-Kinda S; Hess G; Ohler A; Eskelund C; Re A; Ferrarini I; Kolstad A; Räty R; Quaglia FM; Bernardelli A; Eyre TA; Scapinello G; Stefani PM; Morello L; Nassi L; Hohaus S; Ragaini S; Zilioli VR; Bruna R; Cocito F; Arcari A; Jerkeman M
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):476-477
How to choose between curative radiotherapy or chemotherapy in low stage MCL?—a population‐based analysis of outcome in patients with stage I‐II MCL in Sweden
Albertsson‐Lindblad A; Ekberg S; Glimelius I; Ellin F; Sonnevi K; Lewerin C; Smedby KE; Jerkeman M
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41 Suppl 2:471-472
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
Ekberg S; Glimelius I; Albertsson-Lindblad A; Weibull CE
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41 Suppl 2:475-476
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
Abalo K; Smedby KE; Ekberg S; Eloranta S; Pahnke S; Albertsson-Lindblad A; Jerkeman M; Glimelius I
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41 Suppl 2:472-474
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
Wang Y; Larson MC; Ekberg S; Smedby KE; Zhao EJ; Gerrie AS; Farooq U; Maurer MJ; Paludo J; Nowakowski GS; Habermann TM; Albertsson-Lindblad A; Glimelius I; Link BK; Diego V; Jerkeman M; Cerhan JR
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):477-478
Enhanced ctDNA Profiling Reveals Molecular Determinants of Response and Resistance in Relapsed and Refractory Mantle Cell Lymphoma (NLG‐MCL7‐VALERIA)
Meriranta L; Kolstad A; Hutchings M; Pasanen A; Niemann CU; Riise J; Christensen JH; Wader KF; Glimelius I; Leppä S; Jerkeman M
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):369-370
Secondary cancer is the leading cause of death 15 years or more after diagnosis of early‐stage Hodgkin lymphoma
Lagerlöf I; Fohlin H; Enblad G; Glimelius B; Goldkuhl C; Palma M; Glimelius I; Molin D
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41 Suppl 2:746-748
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
Nikkarinen A; Lokhande L; Amini R; Jerkeman M; Porwit A; Molin D; Enblad G; Kolstad A; Räty R; Hutchings M; Weibull CE; Hollander P; Ek S; Glimelius I
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(16_SUPPL):tps7595
waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies
Zinzani PL; Mayer J; Benjamini O; Berkovits A; Glimelius I; Stevens DA; Chaudhry A; Muzaffer Demir A; Garcia Sanz R; Seog Kim W; Li F; Halka J; Marin-Niebla A; Ozcan M; Paszkiewicz-Kozik E; Santoro A; Ren Y; Ogbu U; Marinello P; Jurczak W
Article: CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2023;32(5):687-696
Comparative Analysis of the Humoral Immune Response to the EBV Proteome across EBV-Related Malignancies
Argirion I; Pfeiffer RM; Proietti C; Coghill AE; Yu KJ; Middeldorp JM; Sarathkumara YD; Hsu W-L; Chien Y-C; Lou P-J; Wang C-P; Rothman N; Lan Q; Chen C-J; Mbulaiteye SM; Jarrett RF; Glimelius I; Smedby KE; Hjalgrim H; Hildesheim A; Doolan DL; Liu Z
Article: INTERNATIONAL JOURNAL OF EPIDEMIOLOGY. 2023;52(2):450-465
Sex differences in childhood cancer risk among children with major birth defects: a Nordic population-based nested case-control study
Daltveit DS; Klungsoyr K; Engeland A; Ekbom A; Gissler M; Glimelius I; Grotmol T; Madanat-Harjuoja L; Ording AG; Sorensen HT; Troisi R; Bjorge T
Journal article: EUROPEAN UROLOGY. 2023;83:s1072
Low rate of teratoma in primary retroperitoneal lymph node dissection for non-seminoma csiia marker negative patients - a population-based study from the swedish and norwegian testicular cancer group
Gerdtsson A; Thor AT; Grenabo BAGB; Almas BA; Negaard HF; Glimelius I; Halvorsen DH; Karlsdottir AK; Haugnes HSH; Larsen SML; Holmberg GH; Wahlqvist RW; Tandstad TT; Cohn-Cedermark GCC; Kjellman AK; Stahl OS
Article: AMERICAN JOURNAL OF EPIDEMIOLOGY. 2023;192(1):70-83
Maternal Health, Pregnancy and Offspring Factors, and Maternal Thyroid Cancer Risk: A Nordic Population-Based Registry Study
Kitahara CM; Daltveit DS; Ekbom A; Engeland A; Gissler M; Glimelius I; Grotmol T; Lagerros YT; Madanat-Harjuoja L; Mannisto T; Sorensen HT; Troisi R; Bjorge T
Journal article: HEMASPHERE. 2022;6(Suppl ):42
P091: Early analysis of the PRO-Hodgkin study: Clinical investigation of pencil beam scanning proton treatment in Hodgkin lymphoma patients
Goldkuhl C; Dasu A; Bäck A; Enblad G; Glimelius I; Hall A; Hansson L; Jerlström. U; Johansson A-S; Kahlmeter-Brandell J; Linderoth J; Palma M; Rylander H; Enmark M; Molin D
Journal article: HEMASPHERE. 2022;6(Suppl ):37-38
T082: AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients
Övergaard N; Lia K; Asdahl P; Wikman P; Glimelius I; Lagerlöf. I; Johansson A-S; Hansson L; Enblad G; Linderoth J; Goldkuhl C; Fosså A; Kamper P; Molin D
Journal article: HEMASPHERE. 2022;6(Suppl ):44
P096: Polymorphisms in SETD7 may predispose the risk of developing late cardiac side effects after radiotherapy including the mediastinum in Hodgkin’ s lymphoma.
Linderoth J; Freyhult E; Andreasson E; Johansson A-S; Andersson A; Glimelius I; Enblad G; Molin D
Journal article: HEMASPHERE. 2022;6(Suppl ):37
P081: Treatment-related circulatory diseases and mortality in Hodgkin lymphoma patients using multi-state modelling and relative survival
Baech J; Jakobsen LH; El-Galaly TC; Molin D; Glimelius I; Entrop JP; Crowther MJ; Smedby KE; Eloranta S; Weibull CE
Journal article: HEMASPHERE. 2022;6(Suppl ):30
T065: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
Entrop JP; Weibull CE; Smedby KE; Jakobsen LH; øvlisen AK; Molin D; Glimelius I; Marklund A; Holte H; Fosså A; Smeland KB; El-Galaly TC; Eloranta S
Journal article: ANNALS OF ONCOLOGY. 2022;33:s1197-s1198
1427P The role of anxiety and self-isolation in seropositivity for COVID-19 in actively treated cancer patients in Sweden
Ginman B; Pahnke S; Freyhult E; Hoffman T; Kolstad L; Rönnberg B; Lundkvist Å; Hamberg K; Enblad G; Glimelius I
Journal article: BRITISH JOURNAL OF HAEMATOLOGY. 2022;198(1):11-13
Late relapses in Hodgkin lymphoma - should we search for the needle in the haystack?
El-Galaly TC; Glimelius I
Journal article: AMERICAN JOURNAL OF HEMATOLOGY. 2022;97(7):E255-E257
Cardiovascular disease in patients with chronic lymphocytic leukemia: A Swedish nationwide register study with matched comparators
Larsson K; Soderling J; Hoglund M; Glimelius I; Mattsson M
Journal article: HEMASPHERE. 2022;6(Suppl):983-984
P1093: A NEW PROGNOSTIC MODEL FOR INDIVIDUAL OUTCOME PREDICTION IN ADVANCED‐STAGE HODGKIN LYMPHOMA.
Jørgensen RRK; Eloranta S; Severinsen MT; Øvlisen AK; Smeland KB; Kiserud C; Christensen JH; Hutchings M; Sørensen RB; Kamper P; Glimelius I; Smedby KE; Bergström F; El‐Galaly TC; Jakobsen LH
Journal article: HEMASPHERE. 2022;6:103-104
S202: CHILDBEARING AMONG CLASSICAL HODGKIN LYMPHOMA SURVIVORS TREATED WITH BEACOPP AND ABVD IN SWEDEN, DENMARK, AND NORWAY
Entrop JP; Weibull CE; Smedby KE; Jakobsen LH; Øvlisen AK; Molin D; Glimelius I; Marklund A; Smeland KB; El‐Galaly TC; Eloranta S
Journal article: CANCER RESEARCH. 2022;82(12_Supplement):2026
Abstract 2026: Spatially resolved multiplexed analysisreveals how macrophages adapt to the mantle cell lymphoma microenvironment
Rodrigues JM; Lokhande L; Gerdtsson A; Nikkarinen A; Hollander P; Porwit A; Glimelius I; Jerkeman M; Ek S
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2022;197(5):580-589
Checkpoint CD47 expression in classical Hodgkin lymphoma
Gholiha AR; Hollander P; Lof L; Glimelius I; Hedstrom G; Molin D; Hjalgrim H; Smedby KE; Hashemi J; Amini R-M; Enblad G
Article: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(13):1487-1496
Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy
Lagerlof I; Fohlin H; Enblad G; Glimelius B; Goldkuhl C; Palma M; Akesson L; Glimelius I; Molin D
Article: EUROPEAN UROLOGY ONCOLOGY. 2022;5(2):235-243
Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group
Gerdtsson A; Thor A; Bergdahl AG; Almas B; Hakansson U; Tornblom M; Negaard HFS; Glimelius I; Halvorsen D; Karlsdottir A; Haugnes HS; Andreassen KE; Larsen SM; Holmberg G; Wahlqvist R; Tandstad T; Cohn-Cedermark G; Stahl O; Kjellman A
Article: INTERNATIONAL JOURNAL OF CANCER. 2022;150(5):773-781
Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes
Skold C; Koliadi A; Enblad G; Stalberg K; Glimelius I
Journal article: HAEMATOLOGICA. 2022;107(3):740-743
Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017
Albertsson-Lindblad A; Palsdottir T; Smedby KE; Weibull CE; Glimelius I; Jerkeman M
Article: BLOOD CANCER JOURNAL. 2022;12(1):16
Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark
Jakobsen LH; Ovlisen AK; Severinsen MT; Baech J; Kragholm KH; Glimelius I; Gang AO; Jorgensen JM; Frederiksen H; Poulsen CB; Clausen MR; Pedersen PT; Pedersen RS; Torp-Pedersen C; Eloranta S; El-Galaly TC
Journal article: BLOOD. 2021;138:1344
Late Effects after Treatment in Mantle Cell Lymphoma: No Difference By Intensity of First-Line Regimens with or without Autologous Stem Cell Transplantation
Ekberg S; Smedby KE; Albertsson-Lindblad A; Jerkeman M; Weibull C; Glimelius I
Article: ACTA ONCOLOGICA. 2021;60(11):1459-1465
Clinical characteristics and factors associated with COVID-19-related death and morbidity among hospitalized patients with cancer: a Swedish cohort study
Ullgren H; Camuto A; Rosas S; Pahnke S; Ginman B; Enblad G; Glimelius I; Fransson P; Friesland S; Liu L
Article: JOURNAL OF CLINICAL ONCOLOGY. 2021;39(31):3463-3472
Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study
Ovlisen AK; Jakobsen LH; Eloranta S; Kragholm KH; Hutchings M; Frederiksen H; Kamper P; Dahl-Sorensen RB; Stoltenberg D; Weibull CE; Entrop JP; Glimelius I; Smedby KE; Torp-Pedersen C; Severinsen MT; El-Galaly TC
Journal article: HAEMATOLOGICA. 2021;106(9):2502-2506
Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma
Vajavaara H; Ekeblad F; Holte H; Jorgensen J; Leivonen S-K; Berglund M; Kamper P; Moller HJ; d'Amore F; Molin D; Enblad G; Ludvigsen M; Glimelius I; Leppa S
Article: EJHAEM. 2021;2(3):400-412
Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years
Wahlin BE; Overgaard N; Peterson S; Digkas E; Glimelius I; Lagerlof I; Johansson A-S; Palma M; Hansson L; Linderoth J; Goldkuhl C; Molin D
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;193(5):906-914
Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study
Abu Sabaa A; Morth C; Hasselblom S; Hedstrom G; Flogegard M; Stern M; Andersson P-O; Glimelius I; Enblad G
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;193(3):520-531
Infiltration of CD163-, PD-L1-and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
Rodrigues JM; Nikkarinen A; Hollander P; Weibull CE; Raty R; Kolstad A; Amini R-M; Porwit A; Jerkeman M; Ek S; Glimelius I
Article: BLOOD ADVANCES. 2021;5(6):1671-1681
Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma
Gholiha AR; Hollander P; Glimelius I; Hedstrom G; Molin D; Hjalgrim H; Smedby KE; Hashemi J; Amini R-M; Enblad G
Article: BLOOD ADVANCES. 2021;5(6):1638-1647
Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival
Glimelius I; Smedby KE; Albertsson-Lindblad A; Crowther MJ; Eloranta S; Jerkeman M; Weibull CE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(3):551-559
Clinical characteristics and outcomes among 2347 patients aged ≥85 years with major lymphoma subtypes: a Nordic Lymphoma Group study
Wasterlid T; Oren Gradel K; Eloranta S; Glimelius I; El-Galaly TC; Frederiksen H; Smedby KE
Article: LANCET DIABETES & ENDOCRINOLOGY. 2021;9(2):94-105
Maternal health, in-utero, and perinatal exposures and risk of thyroid cancer in offspring: a Nordic population-based nested case-control study
Kitahara CM; Daltveit DS; Ekbom A; Engeland A; Gissler M; Glimelius I; Grotmol T; Lagerros YT; Madanat-Harjuoja L; Mannisto T; Sorensen HT; Troisi R; Bjorge T
Article: HEMASPHERE. 2021;5(1):e510
Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3
Eskelund CW; Dimopoulos K; Kolstad A; Glimelius I; Raty R; Gjerdrum LMR; Sonnevi K; Josefsson P; Nilsson-Ehle H; Bentzen HHN; Fagerli UM; Kuittinen O; Haaber J; Niemann CU; Pedersen LB; Larsen MT; Geisler CH; Hutchings M; Jerkeman M; Gronbaek K
Article: BMJ-BRITISH MEDICAL JOURNAL. 2020;371:m4060
Cancer risk in individuals with major birth defects: large Nordic population based case-control study among children, adolescents, and adults
Daltveit DS; Klungsoyr K; Engeland A; Ekbom A; Gissler M; Glimelius I; Grotmol T; Madanat-Harjuoja L; Ording AG; Saether SMM; Sorensen HT; Troisi R; Bjorge T
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;191(5):796-805
p53 is associated with high-risk and pinpointsTP53missense mutations in mantle cell lymphoma
Rodrigues JM; Hassan M; Freiburghaus C; Eskelund CW; Geisler C; Raty R; Kolstad A; Sundstrom C; Glimelius I; Gronbaek K; Kwiecinska A; Porwit A; Jerkeman M; Ek S
Journal article: BLOOD. 2020;136:15
Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible
Jerkeman M; Kolstad A; Niemann CU; Groenbaek K; Hutchings M; Pasanen A; Ekberg S; Wader KF; Glimelius I
Article: ACTA ONCOLOGICA. 2020;59(8):949-958
Birthweight and all-cause mortality after childhood and adolescent leukemia: a cohort of children with leukemia from Denmark, Norway, Sweden, and Washington State
Ording AG; Christensen LB; Bjorge T; Doody DR; Ekbom A; Glimelius I; Grotmol T; Larfors G; Mueller BA; Smedby KE; Tretli S; Troisi R; Sorensen HT
Journal article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;190(4):e245-e248
High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: a nationwide population-based study
Larsson K; Mattsson M; Ebrahim F; Glimelius I; Hoglund M
Article: BRITISH JOURNAL OF CANCER. 2020;123(1):161-166
Pregnancy-related risk factors for sex cord-stromal tumours and germ cell tumours in parous women: a registry-based study
Skold A; Bjorge T; Ekbom A; Engeland A; Gissler M; Grotmol T; Madanat-Harjuoja L; Ording AG; Trabert B; Tretli S; Troisi R; Sorensen HT; Glimelius I
Article: EJHAEM. 2020;1(1):199-207
Marginal zone lymphoma expression of histidine-rich glycoprotein correlates with improved survival
Skare TP; Sjoberg E; Berglund M; Smith RO; Roche FP; Lindskog C; Sander B; Glimelius I; Gholiha AR; Enblad G; Amini R-M; Claesson-Welsh L
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;189(6):1083-1092
Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century - a Swedish lymphoma register study
Ekberg S; Smedby K; Glimelius I; Nilsson-Ehle H; Goldkuhl C; Lewerin C; Jerkeman M; Eloranta S
Article: EUROPEAN UROLOGY ONCOLOGY. 2020;3(3):382-389
Surgical Complications in Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumour: A Population-based Study from the Swedish Norwegian Testicular Cancer Group
Gerdtsson A; Hakansson U; Tornblom M; Jancke G; Negaard HFS; Glimelius I; Halvorsen D; Karlsdottir A; Haugnes HS; Andreassen KE; Larsen SM; Holmberg G; Wahlqvist R; Tandstad T; Cohn-Cedermark G; Stahl O; Kjellman A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;189(1):106-116
Comorbidities and sex differences in causes of death among mantle cell lymphoma patients - A nationwide population-based cohort study
Glimelius I; Smedby KE; Eloranta S; Jerkeman M; Weibull CE
Article: INTERNATIONAL JOURNAL OF CANCER. 2020;146(6):1523-1531
Associations of pregnancy-related factors and birth characteristics with risk of endometrial cancer: A Nordic population-based case-control study
Trabert B; Troisi R; Grotmol T; Ekbom A; Engeland A; Gissler M; Glimelius I; Madanat-Harjuoja L; Sorensen HT; Tretli S; Gulbech Ording A; Bjorge T
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;188(5):685-691
No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy
Lagerlof I; Holte H; Glimelius I; Bjorkholm M; Enblad G; Erlanson M; Fluge O; Fohlin H; Fossa A; Goldkuhl C; Gustavsson A; Johansson A-S; Linderoth J; Nome O; Palma M; Akesson L; Ostenstad B; Raud C; Glimelius B; Molin D
Journal article: AMERICAN JOURNAL OF HEMATOLOGY. 2020;95(2):E36-E38
Increasing prevalence of chronic lymphocytic leukemia with an estimated future rise: A nationwide population-based study
Mattsson M; Sandin F; Kimby E; Hoeglund M; Glimelius I
Article: IMMUNOBIOLOGY. 2020;225(1):151872
Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma
Hollander P; Ginman B; Molin D; Enblad G; Amini R-M; Glimelius I
Article: INTERNATIONAL JOURNAL OF CANCER. 2019;145(5):1200-1208
Temporal trends in treatment-related incidence of diseases of the circulatory system among Hodgkin lymphoma patients
Weibull CE; Bjorkholm M; Glimelius I; Lambert PC; Andersson TML; Smedby KE; Dickman PW; Eloranta S
Article: CANCER MEDICINE. 2019;8(10):4918-4927
Distribution of hospital care among pediatric and young adult Hodgkin lymphoma survivors-A population-based cohort study from Sweden and Denmark
Glimelius I; Englund A; Rostgaard K; Smedby KE; Eloranta S; Brown PDN; Johansen C; Kamper P; Ljungman G; Hjalgrim LL; Hjalgrim H
Journal article: HEMATOLOGICAL ONCOLOGY. 2019;37(S2):242
EARLY PROGRESSION OF MANTLE CELL LYMPHOMA DEPICTS A HIGH‐RISK DISEASE WITH POOR RESPONSE TO SUBSEQUENT THERAPIES AND A DISMAL OUTCOME
Eskelund CW; Kolstad A; Glimelius I; Räty R; Gjerdrum LR; Sonnevi K; Josefsson P; Nilsson‐Ehle H; Bentzen H; Fagerli U; Kuittinen O; Haaber J; Pedersen LB; Larsen MT; Geisler CH; Hutchings M; Jerkeman M; Grønbæk K
Journal article: HEMASPHERE. 2019;3(S1):141-142
PF379 PREVALENCE AND INCIDENCE OF CARDIOVASCULAR DISEASE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A NATION‐WIDE POPULATION‐BASED STUDY
Larsson K; Mattsson M; Ebrahim F; Glimelius I; Höglund M
Article: PLOS MEDICINE. 2019;16(6):e1002816
Cancer therapy and risk of congenital malformations in children fathered by men treated for testicular germ-cell cancer: A nationwide register study
Al-Jebari Y; Glimelius I; Nord CB; Cohn-Cedermark G; Stahl O; Tandstad T; Jensen A; Haugnes HS; Daugaard G; Rylander L; Giwercman A
Article: JOURNAL OF INTERNAL MEDICINE. 2019;285(4):455-468
Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study
Wasterlid T; Mohammadi M; Smedby KE; Glimelius I; Jerkeman M; Bottai M; Eloranta S
Article: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(9):703-713
Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study
Biccler JL; Glimelius I; Eloranta S; Smeland KB; Brown PDN; Jakobsen LH; Frederiksen H; Jerkeman M; Fossa A; Andersson TML; Holte H; Bogsted M; El-Galaly TC; Smedby KE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2019;184(2):192-201
High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms
Gholiha AR; Hollander P; Hedstrom G; Sundstrom C; Molin D; Smedby KE; Hjalgrim H; Glimelius I; Amini R-M; Enblad G
Article: INTERNATIONAL JOURNAL OF CANCER. 2018;143(8):1904-1913
Pregnancy complications and subsequent breast cancer risk in the mother: a Nordic population-based case-control study
Troisi R; Ording AG; Grotmol T; Glimelius I; Engeland A; Gissler M; Trabert B; Ekbom A; Madanat-Harjuoja L; Sorensen HT; Tretli S; Bjorge T
Article: INTERNATIONAL JOURNAL OF CANCER. 2018;143(8):1858-1867
Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women
Skold C; Bjorge T; Ekbom A; Engeland A; Gissler M; Grotmol T; Madanat-Harjuoja L; Ording AG; Stephansson O; Trabert B; Tretli S; Troisi R; Sorensen HT; Glimelius I
Article: PLOS ONE. 2018;13(9):e0204870
Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma
Hollander P; Amini R-M; Ginman B; Molin D; Enblad G; Glimelius I
Article: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(26):2718-2725
Contemporarily Treated Patients With Hodgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators
Weibull CE; Johansson ALV; Eloranta S; Smedby KE; Bjorkholm M; Lambert PC; Dickman PW; Glimelius I
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2018;101(1):106-114
Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphomaA population-based study from Sweden
Bjorkholm M; Weibull CE; Eloranta S; Smedby KE; Glimelius I; Dickman PW
Article: JOURNAL OF INTERNAL MEDICINE. 2018;283(5):430-445
The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence
Troisi R; Bjorge T; Gissler M; Grotmol T; Kitahara CM; Saether SMM; Ording AG; Skold C; Sorensen HT; Trabert B; Glimelius I
Article: RADIOTHERAPY AND ONCOLOGY. 2018;126(3):424-430
Short- and long-term risks of cardiovascular disease following radiotherapy in rectal cancer in four randomized controlled trials and a population-based register
Chen L; Eloranta S; Martling A; Glimelius I; Neovius M; Glimelius B; Smedby KE
Article: ACTA ONCOLOGICA. 2018;57(2):276-282
Hodgkin lymphoma in children, adolescents and young adults - a comparative study of clinical presentation and treatment outcome
Englund A; Glimelius I; Rostgaard K; Smedby KE; Eloranta S; Molin D; Kuusk T; Brown PDN; Kamper P; Hjalgrim H; Ljungman G; Hjalgrim LL
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2018;100(1):88-97
An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome
Hollander P; Rostgaard K; Smedby KE; Molin D; Loskog A; Brown PDN; Enblad G; Amini R-M; Hjalgrim H; Glimelius I
Article: AMERICAN JOURNAL OF EPIDEMIOLOGY. 2017;186(10):1159-1167
Parental Age and Risk of Lymphoid Neoplasms
Larfors G; Glimelius I; Eloranta S; Smedby KE
Article: BLOOD ADVANCES. 2017;1(18):1427-1439
High proportions of PD-1⁺ and PD-L1⁺ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome
Hollander P; Kamper P; Smedby KE; Enblad G; Ludvigsen M; Mortensen J; Amini R-M; Hamilton-Dutoit S; d'Amore F; Molin D; Glimelius I
Journal article: HEMATOLOGICAL ONCOLOGY. 2017;35(S2):100-101
UNMET MEDICAL NEEDS IN HODGKIN LYMPHOMA WITH SPECIAL FOCUS ON THE ELDERLY – a POPULATION‐BASED STUDY OF PATIENTS DIAGNOSED IN SWEDEN 1973‐2014
Bjorkholm M; Weibull CE; Eloranta S; Ekström‐Smedby K; Glimelius I; Dickman PW
Journal article: HEMATOLOGICAL ONCOLOGY. 2017;35(S2):172-173
MORTALITY RATES REMAIN INCREASED IN YOUNG PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA EVEN AFTER YEARS IN REMISSION: RESULTS FROM A NORDIC LYMPHOMA GROUP STUDY
Biccler J; Glimelius I; Eloranta S; de Nully Brown P; Jakobsen LH; Frederiksen H; Jerkeman M; Bøgsted M
Article: AMERICAN JOURNAL OF EPIDEMIOLOGY. 2017;185(8):681-687
Possible Interaction Between Cigarette Smoking and HLA-DRB1 Variation in the Risk of Follicular Lymphoma
Baecklund F; Foo J-N; Askling J; Eloranta S; Glimelius I; Liu J; Hjalgrim H; Rosenquist R; Padyukov L; Smedby KE
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2017;92(3):251-258
Increased healthcare use up to 10 years among relapse-free Hodgkin lymphoma survivors in the era of intensified chemotherapy and limited radiotherapy
Glimelius I; Eloranta S; Ekberg S; Chang ET; Neovius M; Smedby KE
Article: BRITISH JOURNAL OF CANCER. 2016;115(11):1416-1420
Reproductive history and risk of colorectal adenocarcinoma in parous women: a Nordic population-based case-control study
Bjorge T; Gissler M; Ording AG; Engeland A; Glimelius I; Leinonen M; Sorensen HT; Tretli S; Ekbom A; Troisi R; Grotmol T
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2016;97(5):430-438
The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children
Englund A; Molin D; Enblad G; Karlen J; Glimelius I; Ljungman G; Amini R-M
Article: LEUKEMIA & LYMPHOMA. 2016;57(10):2351-2358
Association between HLA-A1 and-A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder
Kinch A; Sundstrom C; Tufveson G; Glimelius I
Article: JOURNAL OF CANCER SURVIVORSHIP. 2016;10(3):514-523
Lost workdays in uterine cervical cancer survivors compared to the general population: impact of treatment and relapse
Everhov AH; Ekberg S; Hirschberg AL; Bergmark K; Radestad AF; Glimelius I; Smedby KE
Article: CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2016;25(6):987-994
Work Loss Duration and Predictors Following Rectal Cancer Treatment among Patients with and without Prediagnostic Work Loss
Chen L; Glimelius I; Neovius M; Ekberg S; Martling A; Eloranta S; Smedby KE
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2016;51(5):583-589
Risk of lymphoid neoplasms in a Swedish population-based cohort of 337,437 patients undergoing appendectomy
Mohammadi M; Song H; Cao Y; Glimelius I; Ekbom A; Ye W; Smedby KE
Article: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(4):337-344
Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma
Weibull CE; Eloranta S; Smedby KE; Bjorkholm M; Kristinsson SY; Johansson ALV; Dickman PW; Glimelius I
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2015;90(12):1128-1134
Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics
Glimelius I; Ekberg S; Jerkeman M; Chang ET; Bjorkholm M; Andersson TML; Smedby KE; Eloranta S
Article: CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2015;24(12):1838-1843
A Novel Risk Locus at 6p21.3 for Epstein-Barr Virus-Positive Hodgkin Lymphoma
Delahaye-Sourdeix M; Urayama KY; Gaborieau V; Veenstra R; Foll M; Chabrier A; Benavente Y; Nieters A; Becker N; Foretova L; Maynadie M; Staines A; Smedby KE; Glimelius I; Lightfoot T; Cocco P; Galan P; Vatten LJ; Duell EJ; Kiemeney L; Roman E; de Sanjose S; Lathrop M; Melbye M; Brennan P; Diepstra A; Van den Berg A; Hjalgrim H; Jarrett RF; McKay JD
Article: JOURNAL OF CANCER SURVIVORSHIP. 2015;9(4):599-609
Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time-a population-based comparative study
Glimelius I; Ekberg S; Linderoth J; Jerkeman M; Chang ET; Neovius M; Smedby KE
Journal article: JOURNAL OF CANCER SURVIVORSHIP. 2015;9(4):610-611
Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time-a population-based comparative study (vol 9, pg 599, 2015)
Glimelius I; Ekberg S; Linderoth J; Jerkeman M; Chang ET; Neovius M; Smedby KE
Article: ACTA ONCOLOGICA. 2015;54(10):1770-1780
Sick leave and disability pension among Swedish testicular cancer survivors according to clinical stage and treatment
Nord C; Olofsson S-E; Glimelius I; Cedermark GC; Ekberg S; Cavallin-Stahl E; Neovius M; Jerkeman M; Smedby KE
Article: BMC CANCER. 2015;15:850
The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study
Mohammadi M; Cao Y; Glimelius I; Bottai M; Eloranta S; Smedby KE
Article: AMERICAN JOURNAL OF EPIDEMIOLOGY. 2015;182(7):624-632
Autoimmune and Atopic Disorders and Risk of Classical Hodgkin Lymphoma
Hollander P; Rostgaard K; Smedby KE; Chang ET; Amini R-M; Brown PDN; Glimelius B; Adami H-O; Melbye M; Glimelius I; Hjalgrim H
Article: BJS-BRITISH JOURNAL OF SURGERY. 2015;102(11):1426-1432
Risk of disability pension in patients following rectal cancer treatment and surgery
Chen L; Glimelius I; Neovius M; Eloranta S; Ekberg S; Martling A; Smedby KE
Article: BLOOD. 2013;122(20):3492-3499
Exposure to UV radiation and risk of Hodgkin lymphoma: a pooled analysis
Monnereau A; Glaser SL; Schupp CW; Smedby KE; de Sanjosé S; Kane E; Melbye M; Forétova L; Maynadié M; Staines A; Becker N; Nieters A; Brennan P; Boffetta P; Cocco P; Glimelius I; Clavel J; Hjalgrim H; Chang ET
Article: HISTOPATHOLOGY. 2012;61(1):26-32
Tissue microarray and digital image analysis: a methodological study with special reference to the microenvironment in Hodgkin lymphoma
Glimelius I; Qvarnstrom F; Simonsson M; Ekwall A; Smedby KE; Molin D; Amini R-M
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2011;87(3):208-216
Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkin's Lymphoma - a population-based study
Glimelius I; Rubin J; Rostgaard K; Amini R-M; Simonsson M; Sorensen KM; Smedby KE; Venge P; Hjalgrim H; Molin D; Enblad G
Article: EXPERIMENTAL HEMATOLOGY. 2011;39(8):850-858
Effect of eosinophil cationic protein (ECP) on Hodgkin lymphoma cell lines
Glimelius I; Rubin J; Fischer M; Molin D; Amini R-M; Venge P; Enblad G
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2008;67(1):53-56
Expression of mast cell tryptases in hodgkin and reed-sternberg (HRS) cells
Carvalho RFS; Mahshid Y; Claesson H-E; Glimelius I; Fischer M; Nilsson G
Article: HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA. 2007;21(5):805-823
The potential role of innate immunity in the pathogenesis of Hodgkin's lymphoma
Enblad G; Molin D; Glimelius I; Fischer M; Nilsson G
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2006;76(4):278-283
IL-9 expression contributes to the cellular composition in Hodgkin lymphoma
Glimelius I; Edström A; Amini RM; Fischer M; Nilsson G; Sundström C; Enblad G; Molin D
Journal article: LEUKEMIA. 2005;19(12):2360-2362
Angiogenesis and mast cells in Hodgkin lymphoma
Glimelius I; Edström A; Fischer M; Nilsson G; Sundström C; Molin D; Amini RM; Enblad G
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2003;71(5):327-333
Bulky disease is the most important prognostic factor in Hodgkin lymphoma stage IIB
Glimelius I; Molin D; Amini RM; Gustavsson A; Glimelius B; Enblad G
Article: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2003;290(4):465-475
Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease
Travis LB; Hill DA; Dores GM; Gospodarowicz M; van Leeuwen FE; Holowaty E; Glimelius B; Andersson M; Wiklund T; Lynch CF; Van't Veer MB; Glimelius I; Storm H; Pukkala E; Stovall M; Curtis R; Boice JD; Gilbert E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2002;119(1):122-124
Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma
Molin D; Edström A; Glimelius I; Glimelius B; Nilsson G; Sundström C; Enblad G
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2002;94(3):182-192
Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease
Travis LB; Gospodarowicz M; Curtis RE; Clarke EA; Andersson M; Glimelius B; Joensuu T; Lynch CF; van Leeuwen FE; Holowaty E; Storm H; Glimelius I; Pukkala E; Stovall M; Fraumeni JFJ; Boice JDJ; Gilbert E
Visa fler

Alla övriga publikationer

Conference publication: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2024;24:S483-S484
Zilovertamab Vedotin (ZV) Alone or in Combination With Nemtabrutinib in Relapsed or Refractory (R/R) Aggressive and Indolent B-Cell Malignancies (waveLINE-006): An Open-Label, Phase 2 Basket Study
Paskiewicz-Kozik E; Glimelius I; Moreira C; Garrido M; Ernst D; Jurczak W; Merryman R; Kim WS; Ozcan M; Santoro A; Sawalha Y; Berkovits A; Ren Y; Ogbu U; Yusuf R; Zinzani PL
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(16)
High dose chemotherapy in male patients with germ cell cancer: A population-based study by the SWENOTECA group.
Jansson A; Cohn-Cedermark GE; Negaard HFS; Tandstad T; Stahl O; Hedlund A; Karlsdottir A; Hellstrom M; Langberg CW; Skold C; Haugnes HS; Glimelius I
Review: JOURNAL OF INTERNAL MEDICINE. 2024;295(6):715-734
Malignant ovarian and testicular germ cell tumors: Common characteristics but different prognoses
Skoeld C; Jansson AK; Glimelius I
Review: FRONTIERS IN IMMUNOLOGY. 2024;15:1373269
Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma
Nylund P; Nikkarinen A; Ek S; Glimelius I
Conference publication: AMERICAN JOURNAL OF HEMATOLOGY. 2023;98:S51-S52
Zilovertamab Vedotin Alone or in Combination With Nemtabrutinib in Aggressive and Indolent B-Cell Malignancies: Phase 2waveLINE-006Study
Zinzani PL; Mayer J; Benjamini O; Berkovits A; Glimelius I; Stevens D; Chaudhry A; Demir AM; Garcia Sanz R; Kim WS; Li F; Halka J; Marin-Niebla A; Ozcan M; Paszkiewicz-Kozik E; Santoro A; Ren Y; Ogbu U; Marinello P; Jurczak W
Conference publication: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023;23:S457-S458
Multicohort Study of Conditional Survival and Cause of Death After Achieving Event-Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL)
Wang Y; Larson M; Ekberg S; Smedby K; Zhao E; Gerrie A; Farooq U; Maurer M; Paludo J; Nowakowski G; Habermann T; Albertsson-Lindblad A; Glimelius I; Link B; Villa D; Jerkeman M; Cerhan J
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(16)
Primary retroperitoneal lymph node dissection (RPLND) in seminoma stage IIA-IIC ≤3cm: Combined results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne
Tandstad T; Kjellman A; Almas B; Bergdahl AG; Cohn-Cedermark GE; Gerdtsson A; Glimelius I; Halvorsen DL; Haugnes HSS; Hedlund A; Karlsdottir A; Larsen SM; Negaard HFS; Pfister D; Stahl O; Thor A; Wahlquist R; Heidenreich A; Paffenholz P; Seelemeyer F
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(16)
waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.
Zinzani PL; Mayer J; Benjamini O; Berkovits A; Glimelius I; Stevens DA; Chaudhry A; Demir AM; Sanz RG; Kim WS; Li F; Halka J; Marin-Niebla A; Ozcan M; Paszkiewicz-Kozik E; Santoro A; Ren Y; Ogbu U; Marinello P; Jurczak W
Conference publication: JOURNAL OF UROLOGY. 2023;209:E451
THE EARLY RESULTS OF THE SWENOTECA (SWEDISH NORWEGIAN TESTICULAR CANCER GROUP) INTRODUCTION OF PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) IN SEMINOMA STAGE IIA-IIB ≤ 3CM
Thor A; Gerdtsson A; Almas B; Halvorsen D; Cedermark GC; Neegaard H; Glimelius I; Haugnes HS; Karlsdottir A; Stahl O; Larsen SM; Bergdahl AG; Tandstad T; Kjellman A
Published conference paper: BLOOD ADVANCES. 2023;7(5):866-874
Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation
Ekberg S; Smedby KE; Albertsson-Lindblad A; Jerkeman M; Weibull CE; Glimelius I
Conference publication: BLOOD. 2022;140:9411-9412
Treatment-Related Circulatory Diseases and Mortality in Hodgkin Lymphoma Patients Using Multi-State Modelling and Relative Survival
Baech J; Jakobsen LH; El-Galaly TCC; Molin D; Glimelius I; Entrop JPP; Crowther M; Smedby KE; Eloranta S; Weibull CE
Conference publication: BLOOD. 2022;140:1079-1081
Reproduktiv Patterns Among Non-Hodgkin Lymphoma Survivors By Subtype in Sweden, Denmark and Norway
Entrop JPP; Weibull CE; Smedby KE; Jakobsen LH; Oevlisen AK; Glimelius I; Marklund A; Larsen TS; Holte H; Fossa A; Smeland KB; El-Galaly TCC; Eloranta S
Conference publication: BLOOD. 2022;140:184-185
Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial
Jerkeman M; Kolstad A; Hutchings M; Pasanen A; Meriranta L; Niemann CU; Jorgensen RRK; El-Galaly TCC; Riise J; Leppa S; Christensen JH; Wader KF; Glimelius I
Conference publication: ANNALS OF ONCOLOGY. 2022;33(7):S777
Risk and mortality of testicular cancer in patients with psychiatric or neurodevelopmental disorders
Jansson AK; Soderling J; Reutfors J; Thor A; Skold C; Cohn-Cedermark G; Stahl O; Smedby KE; Pettersson A; Glimelius I
Conference publication: ANNALS OF ONCOLOGY. 2022;33(7):S1197-S1198
The role of anxiety and self-isolation in seropositivity for COVID-19 in actively treated cancer patients in Sweden
Ginman B; Pahnke S; Freyhult E; Hoffman T; Kolstad L; Ronnberg B; Lundkvist A; Hamberg K; Enblad G; Glimelius I
Conference publication: CANCER RESEARCH. 2022;82(12)
Spatially resolved multiplexed analysisreveals how macrophages adapt to the mantle cell lymphoma microenvironment
Rodrigues JM; Lokhande L; Gerdtsson A; Nikkarinen A; Hollander P; Porwit A; Glimelius I; Jerkeman M; Ek S
Conference publication: JOURNAL OF UROLOGY. 2022;207(5):E845
PREDICTING THE HISTOPATHOLOGY RESULT OF POST-CHEMO RETROPERITONEAL LYMPH NODE DISSECTION (PC-RPLND)
Gerdtsson A; Thor A; Bergdahl AG; Negaard H; Almas B; Glimelius I; Karlsdottir A; Halvorsen D; Andreassen KE; Larsen SM; Wahlqvist R; Haugnes HS; Tandstad T; Holmberg G; Cedermark GC; Stahl O; Thorison G; Kjellman A
Conference publication: ANNALS OF ONCOLOGY. 2021;32:S748-S749
Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes
Skold C; Koliadi A; Enblad G; Stalberg K; Glimelius I
Conference publication: BLOOD. 2020;136:3-4
Nationwide Investigation of Patient Trajectories in Mantle Cell Lymphoma - Initial Data from the Swedish MCL Complete Project
Jerkeman M; Palsdottir T; Glimelius I; Albertsson-Lindblad A; Weibull C; Ellin F; Sonnevi K; Lewerin C; Brandefors L; Smedby KE
Conference publication: AMERICAN JOURNAL OF HEMATOLOGY. 2020;95:S14-S15
Prognostic Relevance of IL-6 Expression in the Tumor Microenvironment of Classical Hodgkin Lymphoma
Gholiha AR; Hollander P; Hedstrom G; Molin D; Hjalgrim H; Smedby KE; Glimelius I; Hashemi J; Amini R-M; Enblad G
Conference publication: JOURNAL OF UROLOGY. 2020;203:E384
LOCATION AND HISTOLOGY OF RETROPERITONEAL METASTASES IN POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION FOR NON-SEMINOMA GERM CELL TUMOUR
Gerdtsson A; Thor A; Grenabo A; Almas B; Negaard HFS; Glimelius I; Halvorsen D; Karlsdottir A; Haugnes HS; Andreassen KE; Larsen SM; Holmberg G; Wahlqvist R; Tandstad T; Cohn-Cedermark G; Stahl O; Kjellman A
Conference publication: BLOOD. 2019;134:2841
Fertility Rates in Young Hodgkin Lymphoma Survivors: A Danish Nationwide Cohort Study of 769 Patients
Ovlisen AK; Jakobsen LH; Kragholm KH; Hutchings M; Frederiksen H; Kamper P; Eloranta S; Weibull C; Glimelius I; Smedby KEE; Severinsen MT; El-Galaly TCC
Conference publication: BLOOD. 2019;134:4572
Autologous Stem Cell Transplantation in Mantle Cell Lymphoma - Selection Mechanisms and Survival By Age Group
Glimelius I; Smedby KE; Albertsson-Lindblad A; Eloranta S; Jerkeman M; Weibull C
Review: LEUKEMIA & LYMPHOMA. 2019;60(13):3116-3131
Socioeconomic impact of Hodgkin lymphoma in adult patients: a systematic literature review
Palmarsdottir R; Ovlisen AK; Severinsen MT; Glimelius I; Smedby KE; El-Galaly T
Conference publication: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2019;29:A148-A149
PREGNANCY-RELATED RISK FACTORS FOR SEX CORD-STROMAL TUMORS AND GERM CELL TUMORS IN PAROUS WOMEN: A REGISTRY-BASED STUDY
Skold C; Bjorge T; Ekbom A; Engeland A; Gissler M; Grotmol T; Madanat-Harjuoja L; Ording AG; Trabert B; Tretli S; Troisi R; Sorensen HT; Glimelius I
Preprint: SSRN ELECTRONIC JOURNAL. 2019
Comorbidities and Sex Differences in Causes of Death Among Mantle Cell Lymphoma Patients - A Nationwide Population-Based Cohort Study
Glimelius I; Smedby KE; Eloranta S; Jerkeman M; Weibull CE
Conference publication: BLOOD. 2018;132:2891
Prognostic Implications of Specific Comorbidities in Mantle Cell Lymphoma Patients, a Swedish Lymphoma Registry Study
Glimelius I; Smedby KE; Jerkeman M; Eloranta S; Weibull C
Conference publication: BLOOD. 2018;132:930
Relapse Risk and Loss in Expectation of Lifetime in Young Classical Hodgkin Lymphoma Patients - a Nordic Lymphoma Group Study of 2,582 Patients
Biccler JL; Glimelius I; Eloranta S; Smeland KB; Brown PDN; Jakobsen LH; Frederiksen H; Jerkeman M; Fossa A; Andersson TML; Holte HJ; Bogsted M; El-Galaly TC; Smedby KE
Conference publication: BLOOD. 2018;132:3120
Continuous Increasing Prevalence of Chronic Lymphocytic Leukemia (CLL) with an Estimated Future Rise-a Nationwide Population-Based Study from Sweden
Mattsson M; Sandin F; Kimby E; Hoglund M; Glimelius I
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2017;35:tps4593
The ABC-study: A randomized phase III study comparing one course of adjuvant bleomycin, etoposide, and cisplatin (BEP) and one course of carboplatin AUC7 in clinical stage I seminomatous testicular cancer
Tandstad T; Stahl O; Dahl O; Glimelius I; Haugnes HS; Karlsdottir A; Langberg CW; Soderstrom K; Solberg A; Stierner UK; Wall N; Cohn-Cedermark GE
Review: JOURNAL OF INTERNAL MEDICINE. 2017;281(3):247-260
Novel treatment concepts in Hodgkin lymphoma
Glimelius I; Diepstra A
Conference publication: HAEMATOLOGICA. 2016;101:22
HODGKIN LYMPHOMA IN SWEDEN SINCE 2000: BETTER SURVIVAL ONLY IN ELDERLY WOMEN - A SWEDISH LYMPHOMA REGISTRY STUDY
Wahlin BE; Overgaard N; Peterson S; Digkas E; Glimelius I; Lagerlof I; Johansson A-S; Palma M; Hansson L; Linderoth J; Goldkuhl C; Molin D
Conference publication: HAEMATOLOGICA. 2016;101:36
HODGKIN LYMPHOMA IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS-A COMPARATIVE STUDY OF CLINICAL PRESENTATION AND TREATMENT OUTCOME
Englund A; Glimelius I; Rostgaard K; Eloranta S; Molin D; Kuusk T; Brown PDN; Kamper P; Smedby KE; Hjalgrim H; Ljungman G; Hjalgrim LL
Conference publication: HAEMATOLOGICA. 2016;101:3
PROGNOSTIC IMPLICATIONS OF AN ACTIVE, INNATE OR ANERGIC IMMUNE RESPONSE IN THE HODGKIN LYMPHOMA TUMOR MICROENVIRONMENT
Hollander P; Rostgaard K; Smedby KE; Molin D; Loskog A; Brown PDN; Enblad G; Amini R-M; Hjalgrim H; Glimelius I
Conference publication: HAEMATOLOGICA. 2016;101:1-2
HIGH EXPRESSION OF PROGRAMMED CELL DEATH RECEPTOR 1 IN THE TUMOR MICROENVIRONMENT IS ASSOCIATED WITH INFERIOR EVENT FREE SURVIVAL IN CLASSICAL HODGKIN LYMPHOMA
Hollander P; Kamper P; Smedby KE; Enblad G; Mortensen J; Amini R-M; d'Amore F; Molin D; Glimelius I
Conference publication: HAEMATOLOGICA. 2016;101:64-65
HEALTHCARE USE AMONG YOUNG HODGKIN LYMPHOMA SURVIVORS IN THE ERA OF INTENSIFIED CHEMOTHERAPY AND LIMITED RADIOTHERAPY
Eloranta S; Smedby KE; Ekberg S; Chang E; Neovius M; Glimelius I
Conference publication: ANNALS OF ONCOLOGY. 2011;22:179-180
EVALUATION OF THE NORDIC STUDY FOR EARLY STAGE HODGKIN LYMPHOMA
Raud CG; Enblad G; Melin B; Ostenstad B; Holte H; Lagerlof I; Glimelius I; Goldkuhl C; Linderoth J; Merup M; Fluge O; Molin D
Conference publication: HAEMATOLOGICA. 2007;92:37
Eosinophil cationic protein is cytotoxic to Hodgkin Reed Sternberg cells in vitro -: But why do the eosinophils fail to kill the tumour cells in vivo?
Glimelius I; Eriksson J; Fisher M; Amini RM; Molin D; Venge P; Enblad G
Visa fler

Anställningar

Anknuten till Forskning, Medicin, Solna, Karolinska Institutet, 2023-2026

Om mig

Forskningsbeskrivning

Undervisning

Artiklar

Alla övriga publikationer

Anställningar

Nyheter från KI

Kalenderhändelser från KI